317 Characterization of pharmacokinetics, pharmacodynamics, tolerability and clinical activity in phase I studies of the novel allosteric tyrosine kinase 2 (TYK2) inhibitor NDI-034858

医学 药效学 安慰剂 银屑病 药理学 不利影响 酪氨酸激酶2 银屑病性关节炎 耐受性 银屑病面积及严重程度指数 药代动力学 临床终点 内科学 关节炎 临床试验 免疫学 受体 病理 替代医学 生长因子 血小板源性生长因子受体
作者
E.A. Gangolli,S. Carreiro,J.J. McElwee,N. Dave,A. Lombardi,J. Hanna,V. Hosagrahara,B. Srivastava
出处
期刊:Journal of Investigative Dermatology [Elsevier]
卷期号:142 (8): S54-S54 被引量:2
标识
DOI:10.1016/j.jid.2022.05.325
摘要

Tyrosine kinase 2 (TYK2) is an obligate mediator of signaling via IL-23, IL-12 and the type I interferon receptors, and is a validated therapeutic target in psoriasis and psoriatic arthritis. NDI-034858 is a novel, oral, allosteric, investigational TYK2 inhibitor with high selectivity for TYK2 over JAK1, JAK2, and JAK3 kinases. NDI-034858 was studied in multiple placebo-controlled Phase I studies. These included two trials in healthy volunteers receiving single ascending doses (six dose groups, N = 5-6 per group; versus placebo, N = 12) and multiple ascending doses (four dose groups, N = 6 per group; versus two placebo groups, N = 4 per group) for 2 weeks. NDI-034858 was also studied in patients with moderate to severe psoriasis treated daily for 4 weeks (three dose groups, N = 21 total; versus placebo, N = 5). Across the studies, the pharmacokinetic parameters of NDI-034858 were calculated. Pharmacodynamic effect was tested in a cytokine-induced ex vivo assay using whole blood samples, which demonstrated that exposure to NDI-034858 correlated with activity. No serious adverse events or deaths were observed in the studies, and treatment emergent adverse events were as expected for inhibition of TYK2. Exploratory efficacy endpoint analysis in patients with moderate to severe psoriasis using the Psoriasis Area and Severity Index (PASI) score suggested improvement in the disease. These data support further development of NDI-034858. Phase 2b trials in psoriasis and psoriatic arthritis are ongoing.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
无奈的傲易完成签到,获得积分10
1秒前
2秒前
3秒前
Lucifer完成签到,获得积分10
3秒前
4秒前
高兴曼寒发布了新的文献求助10
4秒前
4秒前
SUE完成签到,获得积分10
5秒前
5秒前
李金奥完成签到 ,获得积分10
5秒前
开心完成签到,获得积分10
6秒前
yang完成签到,获得积分0
7秒前
7秒前
7秒前
爱科研的龙完成签到,获得积分10
7秒前
HeNeArKrXeRn完成签到,获得积分10
7秒前
傻芙芙的完成签到,获得积分10
8秒前
dd发布了新的文献求助10
8秒前
今后应助程程采纳,获得10
8秒前
SciEngineerX完成签到,获得积分10
8秒前
TX应助天使小五哥采纳,获得10
9秒前
fanyy完成签到,获得积分20
9秒前
9秒前
土豪的书蝶完成签到,获得积分10
9秒前
龙傲天发布了新的文献求助10
9秒前
Orange应助张华采纳,获得10
10秒前
Lee完成签到,获得积分10
11秒前
美满的砖头完成签到 ,获得积分10
11秒前
Alice完成签到,获得积分10
11秒前
芳芳子呀发布了新的文献求助20
12秒前
坦率初柔发布了新的文献求助10
13秒前
11完成签到,获得积分10
13秒前
新野发布了新的文献求助10
14秒前
14秒前
明理的踏歌完成签到,获得积分10
14秒前
lxshu0722完成签到,获得积分10
14秒前
体贴的青烟完成签到,获得积分10
15秒前
hh完成签到 ,获得积分10
15秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3151000
求助须知:如何正确求助?哪些是违规求助? 2802506
关于积分的说明 7848292
捐赠科研通 2459791
什么是DOI,文献DOI怎么找? 1309336
科研通“疑难数据库(出版商)”最低求助积分说明 628894
版权声明 601757